• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     NIHR Health Technology Assessment programme Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Corneal collagen crosslinking with riboflavin in keratoconus]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Residents' perspectives of mobile X-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study.
2022     NIHR Health Services and Delivery Research programme Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Adjunctive colposcopy technologies (videocolposcopy) for cervical conditions]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Prenatal cell-free DNA in maternal blood screening to assess chromosomal disorders in single pregnancy]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) The utilization and national variation of plain x-ray services by Australian residents of long-term care facilities
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Antiangiogenic drugs in refractory age-related macular degeneration]
2022     NIHR Health Technology Assessment programme A randomised controlled trial of a protease inhibitor monotherapy versus continuing combination antiretroviral therapy for HIV-1 infected patients previously established on a dual nucleoside and non-nucleoside combination regimen
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2022     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Bariatric surgery in obese patients with gastroesophageal reflux and/or Barrett’s esophagus]
2021     Scottish Medicines Consortium (SMC) Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021     Health Information and Quality Authority (HIQA) Rapid review of public health guidance on protective measures for vulnerable groups in the context of COVID-19
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Scottish Medicines Consortium (SMC) Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021     Health Technology Wales (HTW) Strategies for Relatives (START) intervention to improve the mental health of carers of people with dementia
2021     Health Information and Quality Authority (HIQA) Rolling summary of the evidence in relation to the Omicron (B.1.1.529) variant
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     NIHR Health Technology Assessment programme A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2021     Belgian Health Care Knowledge Centre (KCE) Remote monitoring of patients with cardiovascular implantable electronic devices: a health technology assessment (update of the KCE Report 136)
2021     Health Information and Quality Authority (HIQA) Use of respirator masks by persons who are at higher risk from COVID-19
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     Health Council of the Netherlands Gezondheidsraad (GR) [Influenza vaccination: review of indications]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Rebinyn (nonacog beta pegol) – Type B hemophilia (re-evaluation)]
2021     Health Information and Quality Authority (HIQA) Rapid review of public health guidance for residential care facilities in the context of COVID-19
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Long COVID care pathways: a systematic review
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (primary chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021     Center for Drug Evaluation (CDE) Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sodium zirconium cyclosilicate (hyperkalaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Autologous hematopoietic cell transplant for patients with multiple sclerosis
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Percutaneous repair systems for tricuspid valve insufficiency by annuloplasty]
2021     Adelaide Health Technology Assessment (AHTA) Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021     Center for Drug Evaluation (CDE) Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021     Health Technology Wales (HTW) Oscillating positive expiratory pressure devices for airway clearance in chronic hypersecretory lung conditions
2021     Adelaide Health Technology Assessment (AHTA) Immunoglobulin for chronic inflammatory demyelinating polyneuropathy
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review
2021     Adelaide Health Technology Assessment (AHTA) Genomic testing for the diagnosis of heritable cardiomyopathies
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bedaquiline (multidrug resistant tuberculosis: children aged 5 to 11 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Norwegian Institute of Public Health (NIPH) [Hysterectomy for heavy menstrual bleeding: rapid health technology assessment]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality for TAVI]
2021     Andalusian Health Technology Assessment Area (AETSA) [18F-FDG in myocardial viability for revascularization]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial nutrition in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Addendum to commission H20-05]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Recommendations for the appropriate use of vitamin D tests and supplements in the general population]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pemigatinib (cholangiocarcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Penn Medicine Center for Evidence-based Practice (CEP) Palliative care screening tools
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Addendum to Commission A20-105]
2021     Penn Medicine Center for Evidence-based Practice (CEP) Procalcitonin for antimicrobial discontinuation in hospitalized adult patients
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Second addendum to commission H20-05]
2021     Penn Medicine Center for Evidence-based Practice (CEP) Prone positioning of patients on extracorporeal membrane oxygenation (ECMO)
2021     Health Information and Quality Authority (HIQA) Duration of immunity (protection from reinfection) following SARS-CoV-2 infection
2021     Andalusian Health Technology Assessment Area (AETSA) [Clinical utility of optical coherence tomography angiography in exudative age-related macular degeneration management]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18]
2021     NIHR Health Services and Delivery Research programme Hospital-based specialist palliative care compared with usual care for adults with advanced illness and their caregivers: a systematic review
2021     NIHR Health Technology Assessment programme Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2021     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: thrombotic adverse events with adenovirus vaccines
2021     Andalusian Health Technology Assessment Area (AETSA) [High intensity focused ultrasound (HIFU) in organ-confined prostate tumors]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atidarsagene autotemcel/OTL-200 (metachromatic leukodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     NIHR Health Technology Assessment programme Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT, DAPT plus an anticoagulant) after coronary interventions in the UK: a population based cohort study The ADAPTT Study
2021     NIHR Health Technology Assessment programme High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Process and evaluation of digital health applications in the context of "symptom-checkers"]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabotegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme EMPOWER: Early Signs Monitoring to Prevent Relapse and PrOmote Wellbeing, Engagement and Recovery
2021     Norwegian Institute of Public Health (NIPH) [Natalizumab subcutaneous for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment - health economic evaluation]
2021     Austrian Institute for Health Technology Assessment (AIHTA) National strategies and programmes for preventing and managing non-communicable diseases in selected countries
2021     Malaysian Health Technology Assessment (MaHTAS) Targeted therapies in combination with neoadjuvant chemotherapy for HER2-positive breast cancer and economic evaluation
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme A tailored, psychological intervention for mild to moderate anxiety or depression in people with chronic obstructive pulmonary disease(COPD) (TANDEM Tailored intervention for ANxiety and DEpression Management in COPD)
2021     Norwegian Institute of Public Health (NIPH) [Ofatumumab for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment – health economic evaluation]
2021     Penn Medicine Center for Evidence-based Practice (CEP) Tracheostomy or endotracheal tubes and subglottic suctioning
2021     Malaysian Health Technology Assessment (MaHTAS) Therapeutic drug monitoring (TDM) for anti-tuberculosis
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme High Or Low Dose Syntocinon for delay in labour (HOLDS)
2021     NIHR Health Technology Assessment programme Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users
2021     Health Information and Quality Authority (HIQA) Review of international ethics frameworks used in policy-making in the context of screening
2021     Malaysian Health Technology Assessment (MaHTAS) Custodiol HTK as a replacement of blood cardioplegia in cardiac surgery
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risdiplam (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Specific rehabilitation interventions for physical impairment to avoid chronification of non-specific back pain in adults]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy and safety of onasemnogene abeparvovec, nusinersen and risdiplam for the treatment of spinal muscular atrophy]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Prevention of tuberculosis reactivation
2021     Malaysian Health Technology Assessment (MaHTAS) Mobile C-arm fluoroscopy for cardiothoracic surgery
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Specific versus generic psychological therapy for adolescents with social anxiety disorder: a comparison of Clark & Wells condition-specific cognitive therapy adapted for adolescents, with the generic cognitive behaviour therapy that is currently used in adolescent services
2021     Penn Medicine Center for Evidence-based Practice (CEP) Opioids for vaso-occlusive crisis in pregnant patients
2021     NIHR Health Technology Assessment programme Improving continence in children and young people with neurodisability: a systematic review and survey
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression, acute treatment) - Addendum to Commission A21-25]
2021     Haute Autorite de sante (HAS) [Remote monitoring of patients with an implantable loop recorder]
2021     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: vaccination for women who are pregnant or lactating
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of newborn screening for spinal muscular atrophy]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (urothelial carcinoma) - Addendum to Commission A21-23]
2021     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: management of vaccine-associated thrombotic syndromes